What is HC Wainwright’s Forecast for Ocugen Q1 Earnings?

Posted by Geri Gentry on May 12th, 2026

Ocugen, Inc. (NASDAQ:OCGN – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Ocugen in a research note issued to investors on Monday, May 11th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.07) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen’s Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS and Q4 2027 earnings at ($0.03) EPS.

Ocugen (NASDAQ:OCGN – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $1.53 million during the quarter, compared to analyst estimates of $0.42 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%.

A number of other brokerages have also weighed in on OCGN. Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a report on Thursday, January 22nd. Oppenheimer started coverage on Ocugen in a report on Wednesday, March 11th. They issued an “outperform” rating and a $10.00 price objective on the stock. Wall Street Zen lowered Ocugen from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. Chardan Capital reissued a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a report on Wednesday, March 25th. Finally, Canaccord Genuity Group began coverage on Ocugen in a report on Tuesday, March 17th. They set a “buy” rating and a $12.00 target price on the stock. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.75.

Read Our Latest Research Report on Ocugen

Ocugen Stock Down 2.0%

Shares of OCGN stock opened at $1.48 on Tuesday. The stock’s 50-day simple moving average is $1.86 and its 200-day simple moving average is $1.58. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06. The firm has a market capitalization of $501.01 million, a PE ratio of -6.17 and a beta of 2.30. Ocugen has a fifty-two week low of $0.64 and a fifty-two week high of $2.73.

Institutional Trading of Ocugen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. acquired a new stake in Ocugen during the fourth quarter worth about $1,358,000. ExodusPoint Capital Management LP acquired a new stake in Ocugen during the fourth quarter worth about $155,000. Two Sigma Investments LP acquired a new stake in Ocugen during the third quarter worth about $119,000. Creative Planning acquired a new stake in Ocugen during the second quarter worth about $57,000. Finally, Jump Financial LLC acquired a new stake in Ocugen during the second quarter worth about $57,000. 10.27% of the stock is owned by institutional investors and hedge funds.

Ocugen Company Profile

(Get Free Report)

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.